Press release
Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation
In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will
About this update from Absci Corporation
[{"type":"text","content":"In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medicine veteran Dr. Hubert Truebel will strengthen Absci’s scientific leadership in biologic drug creation.\nVANCOUVER, Wash. and NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the expansion of its Scientific Advisory Board with three world-class scientific leaders: Victor Greiff, Ph.D., Timothy Lu, MD, Ph.D., and Hubert Truebel, MD, Ph.D., MBA. These renowned leaders in AI drug design, synthetic biology, and translational medicine, respectively, will play a pivotal role in helping Absci continue to pioneer AI drug creation in its mission to create better biologics for patients, faster. “We’re proud that our work in AI drug creation has attracted some of the most respected leaders in their fields to join us,” said Dr. Andreas Busch, Chief Innovation Officer at Absci. “It will take the best team in the industry to create life-changing medicines at unprecedented speed, and these three new SAB members reflect Absci’s leading approach to integrating AI and wet biology to create development assets. Dr. Greiff’s expertise in developing machine learning models for in silico antibody design, Dr. Lu’s expertise in biological engineering, and Dr. Truebel’s work in translational medicine give us invaluable expertise that will strengthen Absci’s leadership in in silico drug creation.” Dr. Victor Greiff is an Associate Professor of Systems Immunology at the University of Oslo. Dr. Greiff’s group develops machine learning and experimental tools for analyzing antibody and T-cell repertoires to facilitate the in silico design of immune receptor-based immunodiagnostics and immunotherapeutics. Dr. Greiff earned his Ph.D. from Humboldt-University Berlin, Germany, and conducted his postdoctoral research in the laboratory of Sai T. Reddy at ETH Zürich, Switzerland. A recognized expert in the in silico design of immune receptor-based therapies and diagnostics, Dr. Greiff currently serves as the Executive Sub-committee Chair of the Adaptive Immune Receptor Repertoire Community of The Antibody Society. “Absci’s ability to create and validate antibodies from scratch with AI highlights the breakthrough research occurring at Absci,” said Dr. Greiff. “In silico...